SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around token burns tied to watcher milestones, fueling excitement and perceived scarcity. Talk centers on the strong community, the potential for significant upside, and a desire to reach number one on trending lists. The coin is built on the Solana network and the community is anticipating airdrop details.

Wayfinder

Wayfinder's PROMPT.X is trending with community members citing potential breakouts and significant gains, with some suggesting accumulation during dips. Bullish sentiment is fueled by mentions of strong support levels and potential short squeezes, while others point to increased volume and a possible reversal after a period of decline. The coin is being compared to other altcoins, with some speculating on potential future price targets.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending due to community speculation about a potential acquisition by Nvidia ($NVDA) and excitement surrounding its role in powering AI data centers. Traders are also closely monitoring insider trading activity and the impact of the new CEO on the company's strategic direction within the AI sector. Discussions also include potential breakout opportunities.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as holders tout receiving $SOL.X rewards directly into their wallets just for holding, with the community emphasizing the ease and passive income potential of the token. Discussions highlight the strength and resilience of the community, especially after recent changes and new developments, with a bare knuckle fight sponsorship with Kimbo Slice Jr. also generating buzz.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Pump.fun

$PUMP.X is trending as community members discuss its potential for significant gains, with some highlighting its strong chart and recent updates. Conversations also mention the coin's resilience and potential breakout, with many expressing excitement about its future prospects within the Solana ecosystem. Some users suggest this could be a long-term play, while others are actively trading the volatility.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as discussions emerge around its potential role in decentralized finance and real-world asset tokenization following a U.S. Department of Commerce announcement. The community is focused on Pyth's utility, comparing it to other oracles like Chainlink, and anticipating further price appreciation. Bullish sentiment is fueled by the expectation that the network will disrupt the traditional finance sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cardinal Health (CAH) announced on Thursday the opening of a new distribution center in Fort Worth, Texas, and stated that it will also break ground on a new distribution center in Sacramento, California, this fiscal year.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAH">CAH stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The new 340,000 square foot Texas facility marks the company’s third distribution center built from the ground up in just three years, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/cardinal-health-at-home-solutions-opens-texas-distribution-center-announces-plans-for-new-california-site-302545468.html">said</a>, while adding that it will ship approximately 10,000 packages containing critical medical supplies per day directly to people's homes across the country. &nbsp;The supplies will help manage conditions like diabetes, sleep apnea, and urological conditions, the firm added.The facility is dedicated to the company’s At-Home Solutions business, similar to its buildings in Ohio and South Carolina. The firm also stated that it will break ground on another new site fully dedicated to the at-Home Solutions business in Sacramento this fiscal year. The new Sacramento building is anticipated to be fully operational in summer 2027.Last month, Cardinal Health reported fourth-quarter revenue of $60.2 billion, up from $59.9 billion reported in the corresponding quarter of 2024 and adjusted earnings per share of $2.08, marking a growth of 13% year-on-year.The pharmaceutical and specialty solutions segment, as well as the global medical products and distribution segment, accounted for the majority of the company’s revenue during the period. CAH stock is up 26% this year and approximately 31% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/agios-pharma-stock-slumps-but-company-remains-top-pick-for-analyst/chwdJJlRdYs">Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Cardinal Health is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cardinal Health Opens Distribution Center In Texas, Plans One In California 

The new Texas facility will ship approximately 10,000 packages containing critical medical supplies daily directly to people's homes nationwide.

Equity

Merck (MRK) announced on Tuesday that its investigational oral drug candidate, Enlicitide Decanoate, reduced low-density lipoprotein (LDL-C) cholesterol compared to a placebo in a late-stage trial evaluating the drug for the treatment of Hypercholesterolemia.Hypercholesterolemia is a disorder characterized by elevated LDL cholesterol levels in the blood. According to Merck, it affects about 86 million adults in the U.S. and increases the risk of cardiovascular diseases.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/mercks-investigational-oral-pcsk9-inhibitor-enlicitide-decanoate-met-all-primary-and-key-secondary-endpoints-in-adults-with-hypercholesterolemia-in-pivotal-coralreef-lipids-study/">stated</a> that treatment with Enlicitide resulted in a statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol compared to placebo at week 24. The investigational drug also reduced non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and lipoprotein, the firm said.<a href="https://stocktwits.com/symbol/MRK">MRK shares</a> traded marginally higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around the stock fell from ‘neutral’ to ‘bearish’ over the past 24 hours, while message volume stayed at ‘low’ levels.According to Merck, discontinuations due to adverse events were low and comparable between treatment groups in the trial, which enrolled adults with hypercholesterolemia on a moderate or high intensity statin or with documented statin intolerance. Statins are medications that lower cholesterol by blocking an enzyme in the liver necessary for its production.Merck stated that it plans to share the study's results with regulatory authorities worldwide and present the data at a future scientific congress. Merck Research Laboratories President Deal Y. Li noted that this is the third late-stage trial to demonstrate clinically meaningful and statistically significant LDL-C lowering for Enlicitide.MRK stock is down by about 15% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-stock-slips-over-1-premarket-tech-giant-commits-4-4-b-to-new-zealand-investment/chv6VFeRdnk">Amazon Stock Slips Over 1% Premarket: Tech Giant Commits $4.4B To Expand Asia-Pacific Cloud Reach In New Zealand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck’s Investigational Drug Shows Reduction In Cholesterol In Late-stage Trial

The company reported that treatment with Enlicitide led to a statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol compared to the placebo at week 24.

Nike (NKE) is reportedly planning another round of layoffs expected to impact less than 1% of its corporate staff.According to a CNBC <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/08/28/nike-to-lay-off-about-1percent-of-corporate-staff.html">report</a>, the layoffs will not affect Nike’s EMEA and Converse businesses; however, it is unclear how many jobs will be impacted.Nike announced plans to lay off 2% of its staff previously in February, impacting over 1,500 jobs. The fresh layoffs are part of CEO Elliott Hill’s efforts to realign the business and to change how teams are structured within the corporation, the report said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NKE">NKE stock</a> trended within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.According to the CNBC report, leaders were identified in July to head new sport-focused teams, unlike the previous segmentation of the business into women’s, men’s, and kid’s. A small number of staff will depart as a result of the changes, while some will take on a new position or level, and some others will join a new team or report to a new manager, Nike said in a memo to staff.Employees will get to know if they will be impacted by the layoffs by September 8, and a majority of the new roles will take effect on September 21, the report said. The memo also said that corporate employees based in an office location in the U.S. and Canada will work remotely next week to make space for conversations regarding the layoffs.NKE stock is up by 3% this year but down by about 5% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/judge-to-hear-lisa-cook-case-against-trump-on-friday/chs6h85Rdm6">Judge To Hear Lisa Cook’s Case Against Trump On Friday: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A garden in the shape of a Nike corporate logo is seen in an office building patio in midtown Manhattan on April 6, 2023, in New York City. (Photo by Gary Hershorn/Getty Images)

Nike To Lay Off 1% Corporate Staff: Report

According to a CNBC report, the layoffs will not affect Nike’s EMEA and Converse businesses; however, it is unclear how many jobs will be impacted. 

U.S. auto safety regulator stated on Tuesday that automaker General Motors (GM) is recalling 23,656 Chevrolet Corvette vehicles in the country over heightened risks of fire.The recall involves model year 2023-2026 Corvette vehicles equipped with a left-side radiator or fan combination, including some Corvette convertibles and coupes. Excess fuel may spill into the vehicle fuel-filler pocket during refueling and leak onto an ignition source such as a hot engine or exhaust components, increasing the risk of a fire, the National Highway Traffic Safety Administration (NHTSA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V536-9882.pdf">said</a>.The regulator said that dealers will install a shield to divert spilled fuel, at no cost to the customer, to resolve the issue. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GM">GM stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_9_04_07_AM_png_997caba829.webp" alt="GM's Sentiment Meter and Message Volume as of 9:04 a.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>GM's Sentiment Meter and Message Volume as of 9:04 a.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user noted earlier that the stock will rally soon.<stembedurl>https://stocktwits.com/Derrick20042008/message/626503875</stembedurl>The recall follows an employee submitting a report to the company after reading a social media post alleging that three Corvette vehicles experienced a fire while fueling during a 30-day period. On June 12, a fourth incident occurred in a GM-owned development Corvette test vehicle. GM subsequently opened a product investigation on June 17.GM’s investigation identified four alleged fires that are potentially relevant to the condition. Customer reports, photographs, and video evidence indicated that malfunctioning filling station pumps were a contributing factor in at least two of the four field fires, GM said. It added that two of these incidents involved minor alleged injuries. The company then decided to conduct a safety recall.GM also said in the recall report that owners should always confirm that the fuel nozzle is completely inserted into the vehicle’s fuel pipe before fueling to reduce the risk of fire and turn off the vehicle’s engine during refuelling.GM stock is up by 13% this year and by about 19% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">Why Is Incannex Healthcare Stock Surging Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A new 2025 Chevrolet Corvette on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

GM Recalls Nearly 24,000 Chevrolet Corvette Vehicles In The US: Find Out Why

The recall involves model year 2023-2026 Corvette vehicles equipped with a left-side radiator or fan combination, including some Corvette convertibles and coupes.

Eli Lilly and Company (LLY) announced on Tuesday that its oral weight-loss drug candidate Orforglipron delivered significant weight loss, meaningful average blood glucose reduction, and improvements in cardiometabolic risk factors at 72 weeks in a late-stage trial.At the highest dose of 36 mg, Orforglipron, taken once per day without food and water restrictions, lowered weight by an average of 10.5% compared to 2.2% with placebo, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-successful-third-phase-3-trial">said</a>. The trial studied three doses of Orforglipron in over 1,600 adults with obesity or overweight and type 2 diabetes.Lilly said that it now has the full clinical data package required to initiate global regulatory submissions for Orforglipron.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. LLY stock traded 2.5% higher in the pre-market session at the time of writing.The company said that at 72 weeks, Orforglipron lowered blood sugar levels by 1.3% to 1.8% from a baseline of 8.1% across three doses in the study. Furthermore, at its lowest dose of 6 mg, Orforglipron still delivered a 5.5% average reduction in weight, the company said."With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting,” said Kenneth Custer, Lilly executive vice president and president of Lilly Cardiometabolic Health.The overall safety profile of Orforglipron in the trial was consistent with established GLP-1 receptor agonist class drugs, the company said. The most commonly reported adverse events were gastrointestinal-related and generally mild-to-moderate in severity.The company noted that 6.1% to 10.6% of participants in the study discontinued treatment across doses due to adverse events, as compared to 4.6% with placebo. Overall treatment rates were between 19.1% to 20.5% in patients who received the oral weight loss drug, as compared to 20% with placebo.With Orforglipron, Lilly is attempting to expand its impact in the obesity treatment market dominated by GLP-1 injections. Orforglipron was discovered by Chugai Pharmaceutical Co. and licensed by Lilly in 2018. Lilly is also studying the drug in the treatment of type 2 diabetes, in addition to weight management, and as a potential treatment for obstructive sleep apnea (OSA) and hypertension in adults with obesity.LLY stock is down by 10% this year and by about 27% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/binance-sets-final-500-million-usdt-quota-for-plasma-yield-product/chsHs7sRdje">Binance Sets Final 500 Million USDT Quota For Plasma Yield Product</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly’s Oral Drug Delivers Significant Weight Loss In Late-Stage Study

The company said that it now has the full clinical data package required to initiate global regulatory submissions for Orforglipron.

AbbVie (ABBV) on Monday announced that it will acquire Gilgamesh Pharmaceuticals Inc.'s lead investigational candidate Bretisilocin, which is currently in clinical development for treating patients with moderate-to-severe major depressive disorder (MDD).Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline">deal</a>, AbbVie will acquire Gilgamesh's Bretisilocin program for up to $1.2 billion. This is inclusive of an upfront payment and development milestones, the company said.Bretisilocin is a novel, psychedelic compound. While psychedelic compounds can act as potential treatments for mental health disorders because of their rapid, robust, and durable antidepressant effects, they are also hampered by the long duration of psychoactive experience, AbbVie said.Bretisilocin has been shown to exert a shorter duration of psychoactive experience, while retaining an extended therapeutic benefit, the company added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ABBV">ABBV stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.In May, Gilgamesh Pharmaceuticals said that the investigational drug demonstrated a clinically impactful and statistically significant reduction in the severity of depressive symptoms as compared to a low-dose active comparator in a mid-stage study. Bretisilocin was further well tolerated with no serious adverse events, it addedRoopal Thakkar, chief scientific officer at AbbVie, said that the company looks forward to advancing Bretisilocin to late-stage clinical development.Gilgamesh will also spin off a new entity that will operate under the name Gilgamesh Pharma Inc. to hold its employees and other programs, including the company’s existing collaboration with AbbVie under the terms of the agreement, AbbVie said. The transaction is subject to customary closing conditions.ABBV stock is up by 18% this year and by about 6% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/sharps-technology-stock-rockets-pre-market/chss8BjRd1A">Sharps Technology Stock Just Rocketed 54% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the AbbVie company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AbbVie Seeks To Expand Psychiatry Pipeline By Acquiring Gilgamesh’s Lead Candidate For Up To $1.2B

Gilgamesh's Bretisilocin is in clinical development for treating patients with moderate-to-severe major depressive disorder. 

Johnson &amp; Johnson (JNJ) on Thursday announced it will increase its presence in North Carolina with a 160,000-plus square foot dedicated manufacturing facility, amid President Trump’s push to boost manufacturing in the U.S.The facility will be located at FUJIFILM’s new biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment to Tokyo-based FUJIFILM over the next 10 years will expand the firm’s U.S. manufacturing capacity and create approximately 120 new jobs, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-continues-u-s-investment-with-2-billion-commitment-to-enable-manufacturing-at-state-of-the-art-north-carolina-facility">added</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/JNJ">JNJ stock</a> remained within ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:569/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_9_26_11_AM_png_a8d93f842e.webp" alt="JNJ's Sentiment Meter and Message Volume as of 9:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="569" height="62"><figcaption>JNJ's Sentiment Meter and Message Volume as of 9:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that the company offers stability and a strong dividend now that it is separated from its consumer health division, Kenvue.<stembedurl>https://stocktwits.com/wickHunter007/message/626037111</stembedurl>J&amp;J on Thursday said that it intends to share plans for additional advanced manufacturing facilities in the U.S., as well as the expansion of current U.S. sites, in the coming months.In March, the company announced it would invest $55 billion to support U.S. manufacturing, research and development, and technology investments over the next four years. “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation,” CEO Joaquin Duato said, while adding that the company already has more manufacturing facilities in the U.S. than in any other country.Earlier this month, Trump said he intends to begin imposing a “small tariff” on pharmaceutical imports, with plans to raise it ultimately to 250%.In the second quarter of 2025, J&amp;J reported a 7.8% increase in U.S. sales to $13.54 billion. U.S. sales accounted for 57% of the company’s overall sales in the quarter.Meanwhile, Citi on Thursday raised its price target on JNJ to $200 from $185 while keeping a ‘Buy’ rating on the shares. Citi said that it adjusted targets in the medical technology space following the company’s Q2 report, where the firm said that it had a 7.3% increase in sales in the MedTech segment in the period.JNJ stock is up by 24% this year and by about 11% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/abbvie-investigational-drug-for-alopecia-yields-positive-outcomes-in-late-stage-study/chsSwNARdi9">AbbVie’s Investigational Drug For Alopecia Yields Positive Outcomes In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?

Johnson & Johnson’s new facility will be located at FUJIFILM’s biopharmaceutical manufacturing site in Holly Springs, North Carolina.

Eli Lilly has increased the price of its popular weight loss drug Mounjaro in the U.K. by as much as 170%, The Financial Times reported on Thursday.&nbsp;&nbsp;&nbsp;&nbsp;As per the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/b71a1c59-2735-4ec8-b895-59c562edeeac">report</a>, the price for a month’s supply of the highest doses of the drug will rise from £122 ($165) to £330, an increase of 170%, while prices for lower doses will rise by between 45% and 138%, starting in September. The hike will not affect the price paid by the publicly funded health-care system called the National Health Service, the report added.Lilly <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/statement-americas-leading-role-biopharmaceutical-innovation">stated</a> that the move is aimed at lowering the price for drugs sold in the U.S., in alignment with President Donald Trump’s push for companies to slash U.S. prescription drug prices to match those paid overseas. “This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the U.S.,” the company said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels. According to Stocktwits data, retail chatter around LLY has jumped 430% over the past 30 days as of Thursday morning.<figure class="image"><img style="aspect-ratio:1370/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_12_34_55_PM_png_5d16887591.webp" alt="LLY's Sentiment Meter and Message Volume as of 12:35 p.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="1370" height="130"><figcaption>LLY's Sentiment Meter and Message Volume as of 12:35 p.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they do not see any resistance till a rally to $715 to $720 levels for the stock.<stembedurl>https://stocktwits.com/Bombay55/message/625183980</stembedurl>Lilly said that it has been making efforts to align prices across developed countries, especially in Europe, and expects to make necessary pricing adjustments by September 1. The company, however, noted that underlying structural issues in the U.S. have contributed to high drug prices in the country.“The U.S. system is complex and opaque, with multiple cross subsidies, abuse of government programs like 340B, and insurance cost-sharing burdens for patients,” the firm said.Lilly also pointed out that it opposed the <a href="https://stocktwits.com/news-articles/markets/equity/trump-big-pharma-tariff-call-delayed-white-house-trade-battles-diplomatic-showdowns-report/chsRTc4Rd9z">proposed tariffs</a> on pharmaceutical products, including its medicines, opining that broad tariffs would raise costs and limit patient access. “We urge the administration and Congress to prioritize strategic incentives that strengthen U.S. manufacturing and supply‑chain resilience without sacrificing access, affordability, innovation, or American leadership,” the company said.Trump has previously said that the U.S. would begin imposing a “small tariff” on pharmaceutical imports, with plans to raise it to 150% within 18 months and ultimately to 250%, in an effort to encourage drugmakers to manufacture domestically.LLY stock is down by 13% this year and by about 28% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/analyst-says-sarepta-lost-credibility-by-exiting-arrowhead-at-a-loss/chsRn7vRdON">This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: £1 = $1.35

Eli Lilly To Hike Mounjaro Prices By A Whopping 170% In UK: Retail Expects Stock To See Smooth Rally Till $720

According to the Financial Times, the price for a month’s supply of the highest doses of the drug will rise from £122 to £330, an increase of 170%. 

Eli Lilly (LLY) has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to advance small molecule therapeutics relevant to cardiometabolic diseases and obesity, Superluminal said on Thursday.The collaboration will bring together Superluminal’s drug discovery platform together with Lilly’s expertise in small molecule development and commercialization, Superluminal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.superluminalrx.com/wp-content/uploads/SUN_Lilly_PR_FINAL-with-logo.pdf">said</a>. The platform integrates deep structural biology, machine learning, and proprietary pharmacokinetic and toxicology prediction tools, the company added.Lilly will receive exclusive rights to develop and commercialize compounds arising from the collaboration after privately-held Superluminal delivers the development candidates. The development candidates will target undisclosed G protein-coupled receptors (GPCRs) relevant to cardiometabolic diseases and obesity. GPCRs are a large and diverse family of cell surface receptors that play a crucial role in cell signaling.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels. According to Stocktwits data, retail chatter around LLY has jumped 430% over the past 30 days.Superluminal is eligible to receive up to $1.3 billion under the deal, including upfront and near-term payments, an equity investment, development and commercial milestones, and tiered royalties on net sales.“We are very excited to be embarking on this collaboration just as we begin to advance our internal drug candidate targeting rare genetic forms of obesity and hypothalamic obesity…,” CEO of Superluminal Cony D’Cruz said. Superluminal’s lead program for the treatment of obesity is expected to enter clinical trials in 2026.Superluminal, headquartered in Boston, is backed by names including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Gaingels, and Cooley.LLY stock is down by 14% this year and by about 29% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ppi-report-wholesale-inflation-surges-to-3-3-in-july/chsRSI7RdOJ">PPI Report: Wholesale Inflation In July Comes In Hotter Than Expected</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs

Lilly will receive exclusive rights to develop and commercialize compounds arising from the collaboration. 

Apple Inc. (AAPL) is planning a slew of products, including robots, a lifelike version of Siri, a smart speaker with a display, and home-security cameras, Bloomberg reported on Wednesday, citing people familiar with the matter.The tabletop robot, resembling an iPad mounted on a movable limb that can follow users in a room, is targeted for 2027, the report said. The robot, meant to serve as a virtual companion, is key to the company’s AI strategy, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-13/apple-s-ai-turnaround-plan-robots-lifelike-siri-and-home-security-cameras">noted</a>.According to the report, the company’s plans could be changed or scrapped, given that the products have not been announced yet. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AAPL">AAPL</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.The tabletop robot can turn toward a person who is speaking or calling for it and can even draw the attention of a person not facing it, the report said, while adding that FaceTime calls will also be a key function of the device. The idea is for customers to place it on a desk or kitchen counter and use it to get work done. The device is expected to have a new version of Siri voice assistant that engages in conversations between multiple people, making the device like a person.Meanwhile, Apple is also planning to give Siri a visual personality. The final appearance of Siri’s appearance is yet to be determined, the report added. The project is being led in part by Kevin Lynch, who previously oversaw the company’s push into smart watch software and cars, Bloomberg said. &nbsp;Apple is also developing several other robots and has “loosely discussed” humanoids, while also planning a standalone display, code-named J490, for homes. The display will have home control, music playback, note-taking, web browsing, and video conferencing, the report said.Both the smart display and tabletop robot will run a new operating system dubbed Charismatic, designed to be used by multiple people, Bloomberg said. The company is also planning a smart speaker with a display, slated for 2026.AAPL stock is down by 7% this year but up over 5% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hc-wainwright-doubles-price-target-on-insmed-after-brinsupri-approval/chrCj76Rd9u">HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Customers visit an Apple store at a shopping mall in Kuala Lumpur, Malaysia, on July 15, 2025. Malaysia seeks to lower US tariffs threatened by President Donald Trump to less than 20%. 

Apple Plans Tabletop Robot, Among Other AI Products, Says Report

The tabletop robot, resembling an iPad mounted on a movable limb that can follow users in a room, is targeted for 2027, Bloomberg reported. 

DUHP
Dimensional ETF Trust - Dimensional US High Profitability ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DUHP News

DUHP Dimensional ETF Trust - Dimensional US High Profitability ETF